| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9610409 | SANOFI-AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(2 months ago) | |
| US9233211 | SANOFI-AVENTIS US | Relating to a pen-type injector |
Mar, 2024
(2 months ago) | |
| US8603044 | SANOFI-AVENTIS US | Pen-type injector |
Mar, 2024
(2 months ago) | |
| US9408979 | SANOFI-AVENTIS US | Pen-type injector |
Mar, 2024
(2 months ago) | |
| US9526844 | SANOFI-AVENTIS US | Pen-type injector |
Mar, 2024
(2 months ago) | |
| US9604008 | SANOFI-AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(2 months ago) | |
| US9775954 | SANOFI-AVENTIS US | Pen-type injector |
Mar, 2024
(2 months ago) | |
| US8556864 | SANOFI-AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(2 months ago) | |
| US9827379 | SANOFI-AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(a month ago) | |
| US9011391 | SANOFI-AVENTIS US | Pen-type injector |
Mar, 2024
(a month ago) | |
| US8992486 | SANOFI-AVENTIS US | Pen-type injector |
Jun, 2024
(a month from now) | |
| US9604009 | SANOFI-AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(3 months from now) | |
| US9533105 | SANOFI-AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(3 months from now) | |
| US9623189 | SANOFI-AVENTIS US | Relating to drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(3 months from now) | |
| US9561331 | SANOFI-AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(3 months from now) | |
| US8512297 | SANOFI-AVENTIS US | Pen-type injector |
Sep, 2024
(4 months from now) | |
| US8679069 | SANOFI-AVENTIS US | Pen-type injector |
Apr, 2025
(11 months from now) | |
| US7918833 | SANOFI-AVENTIS US | Pen-type injector |
Sep, 2027
(3 years from now) | |
| US9717852 | SANOFI-AVENTIS US | Cartridge holder and pen-type injector |
Apr, 2033
(8 years from now) | |
Admelog Solostar is owned by Sanofi-Aventis Us.
Admelog Solostar contains Insulin Lispro.
Admelog Solostar has a total of 19 drug patents out of which 10 drug patents have expired.
Expired drug patents of Admelog Solostar are:
- US9610409
- US9233211
- US8603044
- US9408979
- US9526844
- US9604008
- US9775954
- US8556864
- US9827379
- US9011391
Admelog Solostar was authorised for market use on 11 December, 2017.
Admelog Solostar is available in solution;intravenous, subcutaneous dosage forms.
Admelog Solostar can be used as improvement in glycemic control in diabetes mellitus patients by use of a pen injector with a threaded drive sleeve, improvement in glycemic control in diabetes mellitus patients by use of a pen injector with a rotating drive sleeve.
The generics of Admelog Solostar are possible to be released after 08 April, 2033.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 11, 2020 |
Drugs and Companies using INSULIN LISPRO ingredient
Market Authorisation Date: 11 December, 2017
Treatment: Improvement in glycemic control in diabetes mellitus patients by use of a pen injector with a rotating drive sleeve; Improvement in glycemic control in diabetes mellitus patients by use of a pen injec...
Dosage: SOLUTION;INTRAVENOUS, SUBCUTANEOUS
ADMELOG SOLOSTAR family patents
